ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
22.67
+0.37 (1.66%)
At close: Apr 28, 2026, 4:00 PM EDT
22.67
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:01 PM EDT
ACADIA Pharmaceuticals Employees
As of December 31, 2025, ACADIA Pharmaceuticals had 798 total employees, including 796 full-time and 2 part-time employees. The number of employees increased by 144 or 22.02% compared to the previous year.
Employees
798
Change (1Y)
144
Growth (1Y)
22.02%
Revenue / Employee
$1,342,738
Profits / Employee
$489,975
Market Cap
3.87B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| Crinetics Pharmaceuticals | 594 |
| Travere Therapeutics | 497 |
| Catalyst Pharmaceuticals | 182 |
| Edgewise Therapeutics | 146 |
| Tango Therapeutics | 137 |
| NewAmsterdam Pharma Company | 100 |
ACAD News
- 11 days ago - Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting - Business Wire
- 13 days ago - Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - Business Wire
- 21 days ago - Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome - Business Wire
- 6 weeks ago - ACADIA Pharmaceuticals Transcript: Stifel 2026 Virtual CNS Forum - Transcripts
- 6 weeks ago - Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Business Wire
- 6 weeks ago - ACADIA Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 7 weeks ago - Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors - Business Wire
- 2 months ago - Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome - Business Wire